ES2869909T3 - Composiciones y métodos para la modificación del receptor de la proteína tensioactiva A - Google Patents
Composiciones y métodos para la modificación del receptor de la proteína tensioactiva A Download PDFInfo
- Publication number
- ES2869909T3 ES2869909T3 ES15822298T ES15822298T ES2869909T3 ES 2869909 T3 ES2869909 T3 ES 2869909T3 ES 15822298 T ES15822298 T ES 15822298T ES 15822298 T ES15822298 T ES 15822298T ES 2869909 T3 ES2869909 T3 ES 2869909T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- sequence
- monoclonal antibody
- seq
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462024314P | 2014-07-14 | 2014-07-14 | |
| US201562121830P | 2015-02-27 | 2015-02-27 | |
| PCT/US2015/040304 WO2016010978A1 (en) | 2014-07-14 | 2015-07-14 | Compositions and methods for targeting of the surfactant protein a receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2869909T3 true ES2869909T3 (es) | 2021-10-26 |
Family
ID=55078969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15822298T Active ES2869909T3 (es) | 2014-07-14 | 2015-07-14 | Composiciones y métodos para la modificación del receptor de la proteína tensioactiva A |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10077309B2 (https=) |
| EP (2) | EP3733700A1 (https=) |
| JP (1) | JP6495434B2 (https=) |
| CN (1) | CN106604931B (https=) |
| AU (2) | AU2015289831B2 (https=) |
| CA (2) | CA3225495A1 (https=) |
| ES (1) | ES2869909T3 (https=) |
| WO (1) | WO2016010978A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112442126B (zh) * | 2019-09-04 | 2022-07-29 | 杭州济元基因科技有限公司 | 一种抗人cs1抗原的单克隆抗体及其car-t细胞 |
| EP4000597A1 (en) * | 2020-11-17 | 2022-05-25 | The Boots Company plc | Tetrapeptide and compositions comprising tetrapeptides |
| CN116217718B (zh) * | 2022-11-21 | 2023-08-25 | 浙江洪晟生物科技股份有限公司 | 一种猪丹毒抗体检测试剂盒及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE921342A1 (en) * | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| EP1649038B1 (en) | 2003-06-26 | 2014-07-02 | Litron Laboratories Ltd. | Method for the enumeration of micronucleated erythrocyte populations while distinguishing platelets and/or platelet-associated aggregates |
| US8691730B2 (en) * | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| US8748113B2 (en) | 2007-11-15 | 2014-06-10 | The Johns Hopkins University | Methods for detecting and monitoring circulating cancer stem cells |
| WO2010010467A2 (en) * | 2008-07-25 | 2010-01-28 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| CN104936977B (zh) | 2012-10-24 | 2019-10-08 | 开普敦大学 | 微管修饰化合物 |
-
2015
- 2015-07-14 AU AU2015289831A patent/AU2015289831B2/en active Active
- 2015-07-14 WO PCT/US2015/040304 patent/WO2016010978A1/en not_active Ceased
- 2015-07-14 JP JP2017502246A patent/JP6495434B2/ja active Active
- 2015-07-14 EP EP20177668.9A patent/EP3733700A1/en active Pending
- 2015-07-14 CN CN201580042405.4A patent/CN106604931B/zh active Active
- 2015-07-14 ES ES15822298T patent/ES2869909T3/es active Active
- 2015-07-14 US US15/323,858 patent/US10077309B2/en active Active
- 2015-07-14 CA CA3225495A patent/CA3225495A1/en active Pending
- 2015-07-14 EP EP15822298.4A patent/EP3172230B1/en active Active
- 2015-07-14 CA CA2954518A patent/CA2954518C/en active Active
-
2020
- 2020-12-30 AU AU2020294340A patent/AU2020294340B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3225495A1 (en) | 2016-01-21 |
| AU2020294340B2 (en) | 2024-05-02 |
| CN106604931A (zh) | 2017-04-26 |
| CA2954518A1 (en) | 2016-01-21 |
| JP6495434B2 (ja) | 2019-04-03 |
| US10077309B2 (en) | 2018-09-18 |
| EP3733700A1 (en) | 2020-11-04 |
| AU2015289831B2 (en) | 2021-01-28 |
| CN106604931B (zh) | 2020-04-21 |
| US20170158768A1 (en) | 2017-06-08 |
| AU2020294340A1 (en) | 2021-02-25 |
| WO2016010978A1 (en) | 2016-01-21 |
| EP3172230A1 (en) | 2017-05-31 |
| EP3172230A4 (en) | 2018-04-18 |
| JP2017527268A (ja) | 2017-09-21 |
| CA2954518C (en) | 2024-02-20 |
| AU2015289831A1 (en) | 2017-02-09 |
| EP3172230B1 (en) | 2021-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11649292B2 (en) | Compositions and methods for treating and preventing inflammation | |
| KR102312856B1 (ko) | Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신 | |
| ES2965283T3 (es) | Tratamiento de pacientes con hemoglobinuria paroxística nocturna mediante un inhibidor del complemento | |
| ES2647359T3 (es) | Tratamiento de afecciones vasculoproliferativas | |
| ES2881303T3 (es) | Método para el tratamiento o prevención del accidente cerebrovascular | |
| US9493554B2 (en) | Methods of treating retinal disorders with anti-apelin antibodies | |
| TWI786619B (zh) | 抑制scube2，一新穎vegfr2輔受體，遏止腫瘤血管新生 | |
| ES2808529T3 (es) | Inhibidor del factor de células madre | |
| JPWO2016133059A1 (ja) | Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤 | |
| AU2020294340B2 (en) | Compositions and methods for targeting of the surfactant protein a receptor | |
| US20230183323A1 (en) | Methods for preventing, reversing or treating a covid-19 infection | |
| ES2985731T3 (es) | Tratamiento de exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica mediante antagonismo de IL-20R | |
| ES2851386T3 (es) | Método de tratamiento de las heridas | |
| BR112017010336B1 (pt) | Uso de um composto que inibe a sinalização de vegf-b |